Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, such as compounds of the general formula (I): to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.

Abstract: The present application relates to novel (imidazo[1,2-a]pyridin-3-yl)methyl-substituted diazaheterobicyclic compounds, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apnoea and central sleep apnoea and snoring. The present application further relates to a method of discovering a compound having TASK-1- and/or TASK-3-blocking properties.

Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.

Abstract: The present application relates to novel imidazopyridinyl- or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives of formula (I), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring. Formula (I) in which the ring Q represents a bridged 1,4-diazepane cycle.

Abstract: The invention relates to a process for producing pharmaceutical dosage forms containing potent and selective TASK-1 and/or TASK-3 channel inhibitors, and to the use of the dosage forms obtained by the said production process to treat and/or prevent breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring.

Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.

Abstract: The present application relates to novel (imidazo[1,2-a]pyridin-3-yl)methyl-substituted diazaheterobicyclic compounds, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apnoea and central sleep apnoea and snoring. The present application further relates to a method of discovering a compound having TASK-1-and/or TASK-3-blocking properties.

Abstract: The present application relates to novel imidazopyridinyl- or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives of formula (I), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring.

Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.

Abstract: The invention relates to new pharmaceutical dosage forms containing potent and selective TASK-1 and/or TASK-3 channel inhibitors, and the use of same to treat and/or prevent breathing disorders including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring.

Abstract: The invention relates to new pharmaceutical dosage forms containing potent and selective TASK-1 and/or TASK-3 channel inhibitors, and the use of same to treat and/or prevent breathing disorders including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.

Abstract: The present invention provides biocompatible nano-polymer particles which are composed of a biocompatible polymer, a stabilizer and an active agent for the treatment of pulmonary hypertension or erectile dysfunction and which can be used to produce a pharmaceutical preparation for the treatment of pulmonary hypertension or erectile dysfunction. Biocompatible nano-polymer particles of this invention have a diameter ranging from 10 nm to 10 ?m auf, a stabilizing layer thickness between 0 and 50 nm, contain between 0 and 50% of an active agent for the treatment of pulmonary hypertension or erectile dysfunction, are nebulizable and continuously release the active agent over a period of up to 48 hours. Biocompatible nano-polymer particles of this invention can be synthesized for example using the emulsion technique known to the expert with subsequent solvent evaporation or via spray drying.

Abstract: The present invention provides stabilizers for the coating of biocompatible nano- and microparticles which prevent aggregation of the particles during preparation, storage as well as before and after nebulization and which are suitable to be utilized for the manufacture of a pharmaceutical preparation for pulmonary application. Biocompatible nano- and microparticles of this invention have a stabilizer layer thickness ranging from 1 to 200 nm and contain an active substance. Said biocompatible nano- and microparticles of this invention can be synthesized for example using the emulsion method known to the expert with subsequent coating by mixing of uncoated particles with the stabilizer, by chemical vapor deposition, by spraying or by covalent attachment.

Abstract: The present invention provides nano-, meso- and micro-polymer particles which are able to bind pathogenic proteins penetrating into the lining layer of the lung. Known pathogenic proteins in the pulmonary lining layer are negatively charged. These proteins damage the pulmonary surfactant system which is essential to maintain a low surface tension in the lung and thus a functional respiration. Polymer particles of this invention have a diameter between 20 nm and 10 ?m, are water-insoluble, have a positive surface charge and a low surface hydrophobicity. The isoelectric point of said particles is greater than 5 to that said particles are present in the lining layer of the lung as positively charged particles, and at the same time higher than the isoelectric point of the pathogenic protein to be bound. Polymer particles of this invention can for example be prepared using the precipitation or emulsion method.

Abstract: The invention relates to composite materials comprising polymer nanofibers and polymer nanoparticles, wherein at least one of the two polymer materials is loaded with a substance selected from therapeutic and diagnostic agents. Fibers and nanoparticles can comprise identical or different polymers; the polymer materials are, however, biocompatible in every case. Therapeutic and diagnostic agents can be hydrophilic or lipophilic and the two polymer materials likewise. The at least one polymer material and the substance with which said material is loaded are either both hydrophilic or both lipophilic. The polymer nanoparticles of the composite materials have a diameter of 10 nm to 600 nm. The polymer fibers have diameters of 10 nm to 50 ?m and lengths of 1 ?m to several meters. The invention further relates to a method for producing said composite materials.